WHO ICTRP trial
Prevention of severe GVHD after allogeneic hematopoietic stem cell…
NL-OMON47822 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON47822 |
|---|---|
| Public title | Prevention of severe GVHD after allogeneic hematopoietic stem cell transplantation, applied as consolidation immunotherapy in patients with hematological malignancies. A prospective randomized phase III trial. |
| Scientific title | Prevention of severe GVHD after allogeneic hematopoietic stem cell transplantation, applied as consolidation immunotherapy in patients with hematological malignancies. A prospective randomized phase III trial. - HOVON 96 GVHD |
| Primary sponsor | HOVON |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | The Netherlands |
| Conditions | Graft versus Host Disease;10018849;Graft versus Host Disease |
| Interventions | Prevention of GvHD 3 regimens will be compared: a time-restricted immunosuppressive regimen (Myfortic for 28 days and Cyclosporine A for 84 days), a prolonged regimen (Myfortic for 84 days and Cyclosporine A for 180 days) and a short-course… |
| Registration date | Aug 6, 2020 |
| Target size | 497 |
| Secondary IDs | 2008-003540-11;NL27061.078.09;NTR2252 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: